Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Merck Sharp & Dohme LLC
Description:
Heart failure (HF) is a common condition that affects approximately
5.7 million people in the United States, and the prognosis for
patients with heart failure has traditionally been poor. Projections
show that by 2030, the prevalence of heart failure will increase 46
percent from recent estimates. HF is the reason for more than 1
million hospitalizations per year and an estimated $31 billion in
costs in the U.S. each year. While recent efforts have focused on
improving the outlook for patients with chronic heart failure,
mortality and morbidity following admission for heart failure remain
significant. Fortunately for patients with HF, new and emerging
therapeutic options have entered the treatment paradigm in recent
years, including selective cardiac myosin activators, showing the
ability to improve clinical and economic outcomes for the patient
and system, which makes it imperative to update medical directors,
practicing physicians, nurses and other healthcare professionals on
recent clinical data and recommendation updates regarding these new
therapy options.
Upon completion of this
activity, participants will be able to:
-
Review the challenges, clinical
burden, associated comorbidities, and the emerging role of
biomarkers in heart failure (HF)
-
Examine the incidence and prevalence
of HF, the difference between heart failure with preserved or
reduced ejection fraction (HFpEF or HFrEF), diagnostic testing,
and prognosis
-
Compare and contrast new and
emerging therapies, including sGC stimulators and SGLT2
inhibitors, for HF based on mechanism of action, safety, and
efficacy, including options for patients with high-risk HF with
HRrEF
-
Identify patients at high risk for
worsening heart failure to prevent life-threatening events
through prompt intervention
-
Assess clinical practices with
current evidence and guideline-directed medical therapy (GDMT)
for treatment initiation, monitoring, and optimization
-
Examine the cost drivers associated
with the management of heart failure and the value of evolving
novel treatment approaches in lowering cost of care and
healthcare utilization
|
Faculty: |
Akshay Desai, MD, MPH
Medical Director, Cardiomyopathy and Heart Failure
Program, Advanced Heart Disease Section
Brigham and Women's Hospital
Associate Professor
Harvard Medical School |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Desai has served as a consultant for Abbott, Alnylam,
AstraZeneca, Avidity Biopharma, Axon Therapeutics,
Bayer, Biofourmis, Cytokinetics, GlaxoSmithKline, Merck,
Novartis, Medpace, Parexel, Regeneron, River2Renal,
Veristat, Verily, and Zydus. He has received
grant/research support from Abbott, Alnylam, AstraZeneca,
Bayer, Pfizer, and Novartis. His presentation has been
reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
Merck Sharp & Dohme LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |